All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Brentuximab vedotin plus lenalidomide and rituximab for R/R DLBCL: Results from the ECHELON-3
Bookmark this article
|
Results from the phase III ECHELON-3 trial (NCT04404283) of brentuximab vedotin (BV) plus lenalidomide(Len) and rituximab (R) vs placebo (Pbo) plus Len and R in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received ≥2 prior lines of systemic therapy were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Jeong.1 |
| Key learnings: |
|
The phase III ECHELON-3 trial met its primary endpoint of overall survival (OS). |
|
The OS was 13.8 months (median follow up [mFU], 15.5 months) vs 8.5 months (mFU, 18.9 months) in the BV+Len+R and Pbo+Len+R arms, respectively (HR, 0.629; 95% confidence interval [CI] 0.445–0.891; p = 0.0085). |
|
BV+Len+R was associated with improved progression-free survival (PFS) and a higher complete response rate vs Pbo+Len+R: mPFS was 4.2 months vs 2.6 months (HR, 0.527; 95% CI, 0.380–0.729; p < 0.0001) and the ORR rates were 64.3% vs 41.5% (p < 0.0006), respectively. |
|
The safety profile of BV+Len+R was consistent with that of the individual agents. |
| The results from the ECHELON-3 trial suggest that BV+Len+R could be a viable therapeutic option for the treatment of patients with R/R DLBCL, particularly those who cannot receive CAR T-cell therapy or bispecific antibodies or have R/R disease after these treatments. |
- Kim JA. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Abstract #LBA7005. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 30– Jun 3, 2024; Chicago, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
71 votes - 14 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox